Abstract
Background Age at menopause varies widely across women, yet little is known about how this relates to long-term behavioral and brain-structural changes. Previous research has focused primarily on the menopausal transition itself, and the few studies investigating cognitive outcomes suggest reduced age-related cognitive performance with earlier menopause.
Objectives This study aims to investigate whether earlier menopause onset is associated with reduced cognitive performance and brain structure in later-life, in the same cohort of postmenopausal women.
Methods We analyzed data from the Cambridge Centre of Neuroscience and Aging, which included 747 postmenopausal women who underwent cognitive testing (Addenbrooke’s Cognitive Examination Revised, ACE-R). A subset (n=188) was additionally tested with a fluid intelligence test and underwent structural brain scans to measure gray and white matter volume (GMV and WMV). Multiple linear regression models were used to evaluate the association between menopause age and cognitive performance, as well as grey matter volume, controlling for chronological age.
Results Earlier menopause onset was associated with lower cognitive performance, as measured by the ACE-R (t(719)=2.81, p=0.005). Similar results were found for fluid intelligence (t(146) = 3.116, p=0.002). Structural brain analyses showed that a reduction of one year at the age of menopause onset was associated with a reduction of 2370mm3 in total grey matter volume (t(182)=3.37, p=0.001). No significant interactions were observed between menopause onset age and chronological age for any of the outcomes. GMV was a partial mediator between age at menopause onset and cognitive performance, while controlling for age.
Conclusion Women with earlier menopause show both reduced cognitive performance and lower GMV, suggesting that GMV reduction may be one mechanism linking earlier menopause to cognitive decline. However, the cross-sectional nature of this study prevents causal conclusions, and longitudinal research is needed to establish causal links and to explore potential targeted interventions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Cam-CAN research was supported by the Biotechnology and Biological Sciences Research Council. NW was supported by an Israel Science Foundation Personal Research Grant.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Research Ethics Committee of Cambridgeshire 2 (now East of England Cambridge Central) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
